- Home
- CALC vs ACCS Comparison
CALC vs ACCS Comparison
Compare CALC & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- ACCS
- Stock Information
- Founded
- CALC 2011
- ACCS 1988
- Country
- CALC United States
- ACCS United States
- Employees
- CALC N/A
- ACCS N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- ACCS Publishing
- Sector
- CALC Health Care
- ACCS Consumer Discretionary
- Exchange
- CALC Nasdaq
- ACCS Nasdaq
- Market Cap
- CALC 48.1M
- ACCS 46.2M
- IPO Year
- CALC N/A
- ACCS N/A
- Fundamental
- Price
- CALC $3.09
- ACCS $10.70
- Analyst Decision
- CALC Strong Buy
- ACCS Strong Buy
- Analyst Count
- CALC 2
- ACCS 1
- Target Price
- CALC $14.50
- ACCS $14.00
- AVG Volume (30 Days)
- CALC 53.0K
- ACCS 10.7K
- Earning Date
- CALC 08-12-2025
- ACCS 11-06-2025
- Dividend Yield
- CALC N/A
- ACCS N/A
- EPS Growth
- CALC N/A
- ACCS N/A
- EPS
- CALC N/A
- ACCS N/A
- Revenue
- CALC N/A
- ACCS $22,562,000.00
- Revenue This Year
- CALC N/A
- ACCS $0.03
- Revenue Next Year
- CALC N/A
- ACCS $11.45
- P/E Ratio
- CALC N/A
- ACCS N/A
- Revenue Growth
- CALC N/A
- ACCS 26.44
- 52 Week Low
- CALC $1.42
- ACCS $7.79
- 52 Week High
- CALC $5.97
- ACCS $13.35
- Technical
- Relative Strength Index (RSI)
- CALC 56.35
- ACCS 45.67
- Support Level
- CALC $3.04
- ACCS $10.30
- Resistance Level
- CALC $3.38
- ACCS $10.98
- Average True Range (ATR)
- CALC 0.24
- ACCS 0.37
- MACD
- CALC 0.02
- ACCS 0.01
- Stochastic Oscillator
- CALC 58.57
- ACCS 57.45
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.